RxDoctor Payments Data

Pamela Rama-Depadua, MD

Cardiovascular Disease · Jacksonville Beach, FLNPI 1669474086

Payments from drug & device makers

$290,757in general payments, 2019–2025

Across 727 payments — averaging $399.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$202K
  • Abbott$65K
  • AstraZeneca$14K
  • Amgen$1K
  • Pfizer$1K
  • Medtronic$981
  • plus $7K from 39 others

What the payments were for

  • Consulting fees$9,5474%
  • Speaking & faculty fees$188,92483%
  • Travel & lodging$12,7196%
  • Food & beverage$15,5057%
  • Education$3280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$290,757 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$419,562
Medicare patients
2,119
Services billed
5,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban583$727,794
Repatha SureclickEvolocumab249$276,462
XareltoRivaroxaban151$170,281
OzempicSemaglutide113$129,357
EntrestoSacubitril/Valsartan101$123,006
MounjaroTirzepatide73$79,520
FarxigaDapagliflozin Propanediol84$77,802
JardianceEmpagliflozin66$57,973
WegovySemaglutide28$39,816
Praluent PenAlirocumab38$33,744
Nebivolol Hcl358$22,881
MultaqDronedarone Hcl17$18,955
NexletolBempedoic Acid17$16,856
Repatha SyringeEvolocumab14$12,488
Bisoprolol Fumarate351$8,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,109$727,794583 claims
Johnson & JohnsonXarelto$687$170,281151 claims
Novo NordiskOzempic, Wegovy$202,313$169,173141 claims
NovartisEntresto$401$123,006101 claims
Lilly USA, LLCMounjaro$65$79,52073 claims
AstraZenecaFarxiga$13,691$77,80284 claims
Boehringer IngelheimJardiance$352$57,97366 claims
Sanofi-aventis U.S. LLCMultaq$422$18,95517 claims
Esperion Therapeutics, Inc.Nexletol$262$16,85617 claims
AmgenCorlanor$1,128$6,96212 claims
Arbor Pharmaceuticals, Inc.Edarbi$15$4,65812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →